SL-052

• Description:

  SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT) . SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP) -based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations.

• UNSPSC:

  12352005

• Target:

  Photosensitizer

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sl-052.html

• Smiles:

  COC(C([C@H](C(C)=CC1=C(N[C@](CCCC2)([H])[C@@]2([H])N3)C3=C4C5=O)C(C)=O)=C6C1=C4C(C(OC)=C5)=C7C6=C8C(C=C7OC)=O)=C8O

• Molecular Formula:

  C35H32N2O7

• Molecular Weight:

  592.64

• References & Citations:

  [1]Antitumor Efficacy of Photodynamic Therapy Using Novel Nanoformulations of Hypocrellin Photosensitizer SL052

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  925438-34-2